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This article is one of ten reviews selected from the
Annual Update in Intensive Care and Emergency
medicine 2016. Other selected articles can be found
online at http://www.biomedcentral.com/collections/
annualupdate2016. Further information about the
Annual Update in Intensive Care and Emergency
Medicine is available from http://www.springer.com/
series/8901.suggested that MCPE would take the place of angiog-Background
Myocardial perfusion can be safely assessed at the
bedside using contrast echocardiography. The con-
trast agents consist of tiny microbubbles (approxi-
mately 1–8 μm in diameter), which remain in the
systemic circulation for ~ 3–5 min after venous injec-
tion. Low intensity ultrasound imaging is required to
prevent the microbubbles from being destroyed.
Myocardial perfusion is assessed by destroying the
microbubbles with a ‘flash’ of higher intensity ultra-
sound and then analyzing the replenishment rate as
the microbubbles seep back into the myocardial
circulation.
There is reasonable evidence that myocardial contrast
perfusion echocardiography (MCPE) can help in the
detection of coronary artery disease as well as having
prognostic value over regional wall motion analysis.
However, there are challenges in bringing it into every-
day clinical use: the imaging is challenging and relatively
complicated compared to standard echocardiography;
the sensitivity and specificity are not 100 %; it remains
an ‘off‐label’ use of contrast echocardiography; and there
are safety issues to consider. It has been investigated for
more than 25 years and yet still has not made it into
main‐steam cardiac evaluation.* Correspondence: sam.orde@hotmail.com
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© 2016 Orde and McLean.One area of considerable interest and future potential
is in critically ill patients who have raised cardiac en-
zymes, especially troponins, with or without electrocar-
diogram (EKG) abnormalities or regional wall motion
abnormalities, in whom the diagnosis of ischemia needs
to be addressed. Examples include Takotsubo’s or septic
cardiomyopathy. Investigation with angiography or
further imaging may be detrimental in patients with
acute renal failure or bleeding risk and there are dan-
gers associated with unnecessary transfer. It is not
raphy or other investigations assessing myocardial
perfusion, but potentially MCPE could identify pa-
tients (or at least triage them) who have normal myo-
cardial perfusion yet abnormal troponins, EKGs and
have regional wall motion abnormalities. In addition,
there are exciting implications for the future use of
microbubble contrast in terms of drug and gene
delivery.Contrast echocardiography agents
Echocardiography imaging in the critically ill can be
frustratingly difficult at times. Contrast echocardiog-
raphy agents were originally designed to help improve
endocardial border definition, known as left ventricle
opacification, as well as to enhance Doppler signals.
Their use can prevent non‐diagnostic studies from being
inconclusive, particularly in the critically ill [1]. These
contrast agents were originally described in the 1960s
[2] and further development in the 1980s and ’90s saw
specific contrast agents designed to remain in the
systemic circulation after venous injection, as well as
ultrasound imaging enhancement techniques developed
(such as harmonic imaging) to enhance left ventricular
opacification [3–5].
The contrast agents consist of microbubbles contain-
ing a hemodynamically inert gaseous core (e.g., octa-
fluoropropane, sulfur hexafluoride) and a stabilizing
outer shell (e.g., lipid, albumin or biopolymer), which
oscillate under the influence of ultrasound waves [6].
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determine cardiac and intrapulmonary shunts, these
contrast echocardiography microbubbles form multiple
small liquid‐air interfaces whose boundaries have a high
acoustic impedance mismatch resulting in enhanced
ultrasound reflection. A major difference of contrast
microbubbles compared to saline bubbles is the size,
with the bubbles small enough (1–8 μm) to traverse the
pulmonary capillaries in order to enter the systemic cir-
culation. Saline bubbles are typically 50–90 μm diameter
and are destroyed as they pass into the pulmonary
capillaries.
Microbubbles require specific ‘activation’ to be effect-
ive (different methods are required for different agents).
Injected intravenously, they cross the pulmonary circula-
tion into the system circulation. With similar behavior
and rheology to red blood cells (RBCs) [7], they remain
entirely within the vascular compartment and last in the
circulation for approximately 3–5 min before they burst
and lose their ability to produce ultrasound backscatter.
Once the microbubbles are destroyed, the shell is metab-
olized by fatty acid metabolism if made of lipid (such as
with Definity [BMS, Billerica, MA]), or by the reticulo‐
endothelial system. The inert gas is not metabolized and
simply escapes from the lungs [8].
There are various contrast agents available, each
having slightly different compositions and gas cores
(Table 1). Different countries have different agents avail-
able. The first generation contrast agents, developed at
the end of the 20th century, have a lipid shell with an air
core, are soluble and are able to pass through the pul-
monary circulation but lose their echogenicity and dis-
solve rapidly. The second generation contrast agents
were then developed and have high‐molecular weight
gaseous cores, are less soluble than air, with stabilizing
lipid or biopolymer shells and remain more stable under
the ultrasound field and, therefore, have an increasedTable 1 Contrast echocardiography agents
Classification Gas core Shell Trad
First generation Air Albumin Alb




Second generation Octafluoropropane (C3F8) Albumin Opt
Cha
Octafluoropropane (C3F8) Lipid Def
Sulfur hexafluoride (SF6) Lipid Son
NB: The list does not include every available contrast agent worldwide and the accu
writing to the best of the authors’ knowledgelifespan in the circulation [9]. These preparations in-
clude the standard contrast agents used today: Defi-
nity, Optison (GE healthcare, Chalfont St Giles, UK)
and Sonovue (Bracca, Milan, Italy). Third generation
agents include those specifically used for research‐
based activities, specialized imaging or therapeutic
purposes [8].
Effect of ultrasound on contrast agents
Specific imaging techniques and software are required
to perform MCPE to take advantage of the different
ultrasound reflection properties of the contrast micro-
spheres versus soft tissue. When ultrasound interacts
with the microbubbles they oscillate and this effect is
dependent on the ultrasound acoustic pressure as well
as the shell and core gas properties of the agent. Ultra-
sound acoustic pressure is described as the ‘mechanical
index’ and corresponds to the power output of the
scanner [10]. With standard 2D echocardiography im-
aging the mechanical index is ~ 1.4; however, at this
level the microspheres would oscillate to such a degree
that they would burst and be destroyed. Therefore low
mechanical index (< 0.2) imaging is used with contrast
imaging.
The oscillation effect of contrast echocardiography
under low mechanical index ultrasound means the ultra-
sound reflections are different for microbubbles com-
pared to soft tissue. This difference can be harnessed to
enhance contrast versus tissue differentiation when im-
aging: microbubbles reflect ultrasound in a non‐linear
format compared to tissue, which reflects ultrasound in
a linear manner. Non‐linear reflection means the sound
waves are reflected not only at the frequency of the
original ultrasound wave but also at higher, harmonic
frequencies. Soft tissue, however, produces fewer har-
monics, hence reflection of the ultrasound waves in a
more linear fashion. There are different methods usede name Bubble size (μm) Comments
unex 2–8 No longer made
ovist (Schering,
nworth, NJ)
2–8 Non‐cardiac use mainly
ovist (Berlex, Lachine,
bec City, Canada)
2–8 First commercially available
agent
ison (GE healthcare,
lfont St Giles, UK)
1–10 Available in USA, Europe,
South America
inity (BMS, Billerica, MA) 1–10 Available in USA, Europe,
South America, Canada,
Australasia
ovue (Bracca, Milan, Italy) 1–10 Available in Europe and
USA (known as Lumason)
racy of the ‘comments’ section may change but is up to date at time of
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flection properties for tissue vs contrast microbubbles,
including: pulse inversion, power modulation and coher-
ent contrast imaging to reduce the soft tissue linear re-
flections of the fundamental frequency [11].
Myocardial perfusion imaging
In the 1990s, initial studies in animals, subsequently
validated in humans, investigated the hypothesis that
myocardial blood flow could be assessed with contrast
echocardiography by destroying the contrast microbub-
bles with a ‘flash’ of high diagnostic intensity ultrasound
and then assessing the rate of replenishment of the micro-
bubbles into the myocardium [12–14]. The replenishment
is assessed by the change in intensity or brightness in a
‘region of interest’ (ROI). The microbubbles behave like
RBCs, hence the theory that any change in signal intensity
represents a change in myocardial blood flow.
With normal myocardial blood flow, 90 % of the cor-
onary circulation resides within the myocardial capillar-
ies and RBCs travel at approximately 1 mm/s at rest.
After destruction of the contrast the signal intensity is
anticipated to return to normal after approximately 5–7
cardiac cycles [13] (Fig. 1). During stress or exercise
where vasodilation and increased capillary blood flow
are present, the rate of return of signal intensity is faster:
approximately 2–3 cardiac cycles. The rate of microbub-
ble replenishment can be assessed qualitatively (as seen
in Fig. 1), but also quantitatively by reviewing the change
in signal intensity over time in a specific ROI (Fig. 2).
Myocardial blood flow is considered the product of plat-
eau signal intensity and rate of replenishment (Fig. 3). The
concept being that the slower the rate of replenishmentFig. 1 Normal myocardial contrast perfusion echocardiograph: qualitative a
(SS – steady state). A ‘flash’ of high mechanical index ultrasound destroys t
myocardial perfusion is then made as the microbubbles return to the myo
occurs over 5–6 cardiac cycles at rest, 2–3 cardiac cycles with stressand lower the plateau signal intensity, the poorer the myo-
cardial blood flow.
Safety profile
The use of contrast echocardiography, extensively inves-
tigated in several large multicenter trials [15–17], has
been found to be well‐tolerated and safe in both non‐
critically ill and critically ill patients [18]. ‘Black‐box’
warnings were issued by the US Food and Drug Admin-
istration (FDA) in 2007 but these were downgraded
within 12 months. The current FDA recommendations
state that if a patient has an unstable cardiopulmonary
condition or pulmonary hypertension (the severity is not
stated), the patient should have cardiorespiratory moni-
toring for 30 min after contrast agent administration
[19]. In the United States, echocardiography laboratories
are not accredited unless they have the ability to perform
contrast echocardiography [20].
Side effects are rare and include headache, flushing or
back pain. These symptoms are usually relieved on ces-
sation of contrast agent administration. There is a
1:10,000 chance of an anaphylaxis type reaction (consid-
ered secondary to the microbubble shell and possibly
non‐IgE related) [9]. Contraindications include previous
hypersensitivity to contrast agents or to blood products
(e.g., albumin), severe pulmonary hypertension and car-
diac right‐to‐left or bidirectional shunts. These last two
contraindications are under debate and evidence exists
of the safety in these conditions, whereas there are only
case reports of harm with recent use of ultrasound
contrast [16, 21].
We consider an individualized approach of risk versus
benefit is required for MCPE. Important requirementsssessment. Ultrasound contrast infused until steady state achieved
he contrast microbubbles within the imaging beam. Assessment of
cardium over subsequent cardiac cycles (1–6). Normal replenishment
Aβ
Fig. 3 Myocardial contrast perfusion echocardiography (MCPE)
quantitative assessment. Regions of interest (ROI) are defined and
rate of change in signal intensity assessed at end‐diastolic frames.
The plateau signal intensity (A) is considered to represent the
myocardial capillary blood volume. The rate of replenishment (β) of
the microbubbles is considered as the velocity of blood. The
product of A × β is considered to represent the myocardial
blood flow
Fig. 2 Qualitative assessment of myocardial perfusion involves
specification of a region of interest (ROI) classically corresponding to
individual left ventricular myocardial segments
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ure, and the study should be performed in an environ-
ment with appropriate monitoring and resuscitation
facilities.
Applications in the critically ill
Recognition of acute coronary artery disease
The diagnosis of acute coronary syndromes (ACS) in the
intensive care unit (ICU) can be challenging. Critically
ill patients with ischemic heart disease are at greater risk
during times of stress and the classic history of central
crushing chest pain can be absent as a result of acute ill-
ness, sedation and/or mechanical ventilation. Troponin
elevation, EKG and regional wall motion abnormalities
(RWMA) are frequently seen in conditions other than
myocardial infarction [22], for example Takotsubo’s and
septic cardiomyopathy amongst many other causes [23].
In addition, investigating for possible ACS with angiog-
raphy or single photon emission computed tomography
(SPECT) can be dangerous due to the inherent risks of
patient transport, contrast‐induced nephropathy, radi-
ation, access issues, anticoagulation, and delays in diag-
nosis. Cost and access to suitable angiographic facilities
may be issues in some ICUs. Potentially, MCPE could
help identify patients with ACS at the bedside in the
ICU, not to replace further imaging, but rather as a tri-
age tool or simply to add confidence to the physician’s
clinical acumen [24].
MCPE has been compared to SPECT, the most widely
used perfusion technique for assessment of coronary ar-
tery disease. In several studies for detection of coronary
artery disease, MCPE has shown excellent concordance(81 % [76.4–85.6]) [25]. A meta‐analysis indicated a
higher sensitivity for MCPE than for SPECT and no dif-
ference was found for specificity [26]. Various clinical
studies have used MCPE to quantify myocardial blood
flow, trying to differentiate coronary artery ischemia
from not significantly occluded coronary arteries. Senior
et al. reported that MCPE could differentiate ischemic
from non‐ischemic cardiomyopathy (defined as < 50 %
coronary artery stenosis) with a specificity of 89 % and
sensitivity of 91 % [27].
Microvascular versus macrovascular function assessment
Microvascular dysfunction has been proposed in a num-
ber of cardiac conditions such as Takotsubo’s [28] and
septic cardiomyopathy [29] amongst others. Whether
the microvascular dysfunction is a primary cause of sec-
ondary phenomena is not known. Abdelmoneim et al
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confirmed Takotsubo’s syndrome and were able to show
reduced perfusion in the myocardium with a 71 % con-
cordance with areas of RWMA [28]. It is suggested that
the microvasculature in the endocardial regional has the
lowest flow reserve and is more susceptible to ischemia
than the epicardium possibly due to the larger epicardially
placed coronary arteries [30]. Therefore, with microvascu-
lar disorders there may be a reduction in the endocardial
myocardium to a greater extent than in the epicardial
myocardium (Fig. 4).Possible future roles for contrast echocardiography
Advances in contrast microbubble formulations, imaging
and post‐processing analysis, indicate that the future for
contrast echocardiography may include imaging of
macro and microvasculature elsewhere in the body as
well as targeted drug and/or gene delivery.Contrast‐enhanced ultrasound
Using contrast agents in a similar manner to MCPE,
non‐invasive and bedside perfusion assessment of or-
gans may be possible. Schneider et al. suggested that
assessing renal cortical perfusion with contrast is feas-
ible and well‐tolerated in the ICU population and that
possibly a decrease in renal perfusion may occur
within 24 h of surgery in patients at risk of acute kid-
ney injury (AKI) [31]. These techniques are relatively
unexplored at this time and although they hold
promise, do demonstrate significant heterogeneity andFig. 4 Takotsubo’s cardiomyopathy with microvascular dysfunction (arrows
apical region where transient apical hypokinesis was visualized. Coronary a
demonstrated apical ballooningthe results remain unpredictable [32]. Further investi-
gation is certainly warranted.
Targeted drug delivery
The property of contrast microbubbles bursting under
the effect of ultrasound can be used to target drug
delivery. Drugs can be attached to microbubbles by a
variety of methods [10] and as long as the site is ac-
cessible to ultrasound, a burst of high mechanical
index ultrasound may be able to locally deliver the
drug, such as thrombolysis. Transfer of genetic mater-
ial has also been suggested and has been shown to be
safe and more specific than viral vectors for cDNA
delivery [33].
Conclusion
The use of contrast echocardiography in the critically ill
is safe compared to other contrast agents, feasible at the
bedside and has the potential to rescue undiagnostic
echocardiograms. Although the agents are only indicated
for left ventricular opacification, the off‐label use of
MCPE holds promise as being a potential method to as-
sess myocardial perfusion at the bedside. The technology
has been available for over two decades and is yet to find
a place in regular clinical practice, but as a result of ever
evolving sophistication of microbubble agents, software
and hardware still holds considerable promise. The util-
ity of MCPE in the ICU has not been extensively consid-
ered to date but potentially may have a role in the
challenging arena of accurate and timely diagnosis of
ACS in the critically ill.). Endocardial perfusion defect shown at 5 beats post flash in the
ngiography confirmed normal vasculature and left ventriculography
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